EUVIMEDEUVIMED entdecken
Leitlinie

Medical Cannabis Use in Autism: Insights from an Israeli HMO on Patient Characteristics and Alignment with National Guidelines

Hadar Sadeh, Talish Razi, Ronen Arbel, Doron Netzer, Gal Meiri

Journal of Child and Adolescent Psychopharmacology · 2026

DOI: 10.1177/10445463251404404 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, 2026. Verfasst von Hadar Sadeh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Child and Adolescent Psychiatry Unit, Soroka University Medical Center, Beer Sheva, Israel. Hauptthemen laut MEDLINE: Medical Marijuana, Autistic Disorder, Guideline Adherence, Practice Patterns, Physicians'. Die Arbeit nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Evidence for medical cannabis use and effectiveness in autism has begun to accumulate but remains limited, even as clinical interest has rapidly increased. In Israel, medical cannabis may be prescribed for autism with severe behavioral disturbances under strict Ministry of Health criteria requiring prior trials of two Food and Drug Administration (FDA)-approved antipsychotics. Using a large real-world dataset, this study aimed to characterize autistic individuals prescribed medical cannabis and evaluate adherence to national guidelines.

Methods

A retrospective cohort study was conducted using electronic medical records from Clalit Health Services, Israel’s largest Health Maintenance Organization. All individuals with a documented autism diagnosis between 1990 and 2025 were identified ( N = 36,610) and classified as cannabis-prescribed ( N = 462) or not-prescribed ( N = 36,148). Demographic and clinical characteristics were compared, including prior use of FDA-approved antipsychotics.

Results

Only 1.2% of individuals with autism were prescribed medical cannabis. Of these, 4.3% of prescriptions were issued for children under 5 years of age. The cannabis-prescribed group was diagnosed earlier (median 3 vs. 5 years, p < 0.001) and had higher rates of ADHD (42% vs. 30%), intellectual disability (12% vs. 5%), and epilepsy (14% vs. 6%) (all p < 0.001). While 69% had used at least one FDA-approved antipsychotic medication prior to cannabis initiation, only 28% had documented trials of both, as required by national guidelines. Marked sociodemographic disparities were also observed: the cannabis-prescribed group had a higher socioeconomic status (median SES 7 vs. 6, p < 0.001) and lower representation of Arab individuals (2.7% vs. 11%, p < 0.001).

Conclusions

Medical cannabis use among autistic individuals was rare and mainly observed among those with more complex clinical profiles and higher socioeconomic backgrounds. Most prescriptions did not fully comply with guidelines requiring prior antipsychotic trials. These findings underscore the need for enhanced regulatory oversight, equitable access, and longitudinal research to evaluate real-world outcomes and guide evidence-based clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Medical MarijuanaAutistic DisorderGuideline AdherencePractice Patterns, Physicians'HumansIsraelMaleRetrospective StudiesFemaleChildChild, PreschoolAdolescentAntipsychotic AgentsPractice Guidelines as TopicAdultYoung AdultCohort Studies

Stichwörter der Autor:innen

autismcomorbiditiesmedical cannabispatient characteristicstreatment guidelines

Substanzen

Medical MarijuanaAntipsychotic Agents

Autor:innen und Institutionen

  • Child and Adolescent Psychiatry Unit, Soroka University Medical Center, Beer Sheva, Israel.
  • Psychiatry Division, Faculty of Health Science, Ben Gurion University of the Negev, Beer Sheva, Israel.
  • Community Medical Services Division, Clalit Health Services, Tel Aviv, Israel.
  • Maximizing Health Outcomes Lab, Sapir College, Sderot, Israel.
  • Adelson School of Medicine, Ariel University, Tel Aviv, Israel.
  • Azrieli National Center for Autism and Neurodevelopment Research, Ben Gurion University of the Negev, Beer Sheva, Israel.

Zitieren

APA

Sadeh, H., Razi, T., Arbel, R., Netzer, D., & Meiri, G. (2026). Medical Cannabis Use in Autism: Insights from an Israeli HMO on Patient Characteristics and Alignment with National Guidelines. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1177/10445463251404404

Vancouver

Sadeh H, Razi T, Arbel R, Netzer D, Meiri G. Medical Cannabis Use in Autism: Insights from an Israeli HMO on Patient Characteristics and Alignment with National Guidelines. Journal of Child and Adolescent Psychopharmacology. 2026. doi:10.1177/10445463251404404

BibTeX
@article{Sadeh2026,
  author = {Sadeh, Hadar and Razi, Talish and Arbel, Ronen and Netzer, Doron and Meiri, Gal},
  title = {Medical Cannabis Use in Autism: Insights from an Israeli HMO on Patient Characteristics and Alignment with National Guidelines},
  journal = {Journal of Child and Adolescent Psychopharmacology},
  year = {2026},
  doi = {10.1177/10445463251404404}
}
Kostenlos starten →